What is IASO Biotherapeutics?
Founded in 2017, IASO Biotherapeutics is a clinical-stage biotechnology enterprise headquartered in China, specializing in the research and development of next-generation cell therapies. The company focuses on engineering advanced therapeutic solutions designed to target complex malignancies. By integrating cutting-edge molecular biology with robust clinical trial frameworks, IASO Biotherapeutics aims to redefine the standard of care for patients suffering from various forms of cancer. Its market position is defined by a commitment to scientific rigor and the rapid translation of laboratory discoveries into viable clinical applications.
How much funding has IASO Biotherapeutics raised?
IASO Biotherapeutics has raised a total of $235M across 2 funding rounds:
Series B
$60M
Series C
$175M
Series B (2020): $60M with participation from Hillhouse Capital
Series C (2021): $175M led by Everbright Limited, Shanghai Wai Gaoqia Free, CNCB Capital, CDH Baifu, and Co-Stone Capital
Key Investors in IASO Biotherapeutics
Hillhouse Capital
Hillhouse Capital is an Asia-focused global private investment firm that provides long-term capital to high-growth companies across various sectors, including healthcare and biotechnology.
Everbright Limited
Everbright Limited is a diversified financial services firm with a strong emphasis on cross-border investment and asset management in the Asian markets.
CNCB Capital
CNCB Capital is a prominent investment institution specializing in strategic equity financing and supporting the growth of innovative technology and healthcare enterprises.
What's next for IASO Biotherapeutics?
With the successful closure of its latest financing round, IASO Biotherapeutics is poised to enter a critical phase of expansion. The strategic deployment of these funds will likely prioritize the scaling of manufacturing capabilities and the acceleration of ongoing clinical studies. As the company matures, the focus will shift toward regulatory milestones and potential commercialization pathways, ensuring that its therapeutic candidates move efficiently through the pipeline. Investors will be closely monitoring the firm's ability to maintain its competitive edge in the high-stakes cell therapy market, particularly as it navigates the complexities of international clinical standards and long-term efficacy validation.
See full IASO Biotherapeutics company page
